Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -73.54%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-61.34%
RETURN ON EQUITY (ROE) AVG 3Y
-47.94%
RETURN ON EQUITY (ROE) AVG 5Y
-74.47%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CytoMed Therapeutics Limited
Market Cap
$11.00M
Return on Equity (ROE)
N/A
TTM Avg
-61.34%
3Y Avg
-47.94%
5Y Avg
-74.47%
Market Cap
$11.02M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$10.94M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$11.08M
Return on Equity (ROE)
-65.18%
TTM Avg
-26.62%
3Y Avg
-94.28%
5Y Avg
-90.35%
Market Cap
$11.12M
Return on Equity (ROE)
-276.21%
TTM Avg
-134.62%
3Y Avg
-196.35%
5Y Avg
-146.45%
Market Cap
$10.86M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
Market Cap
$10.83M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
Market Cap
$10.68M
Return on Equity (ROE)
N/A
TTM Avg
216.74%
3Y Avg
-5384.23%
5Y Avg
-3626.91%
Market Cap
$11.36M
Return on Equity (ROE)
-506.63%
TTM Avg
-300.20%
3Y Avg
-300.20%
5Y Avg
-300.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $11.00M | N/A | -61.34% | -47.94% | -74.47% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | -177.35% | -89.62% | -75.99% | -59.80% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -477.54% | -207.60% | 64.51% | -22.91% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | -65.18% | -26.62% | -94.28% | -90.35% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | -276.21% | -134.62% | -196.35% | -146.45% |
| BioVie Inc. (BIVI)vs › | $10.86M | -214.92% | -46.13% | -156.76% | -652.77% |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | -22.56% | -244.57% | 3710.91% |
| Pluri Inc. (PLUR)vs › | $10.68M | N/A | 216.74% | -5384.23% | -3626.91% |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -506.63% | -300.20% | -300.20% | -300.20% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | -102.40% | -97.28% | -110.13% | -94.77% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -73.54% |
| 2025-09-30 | -68.43% |
| 2025-06-30 | -59.64% |
| 2025-03-31 | -61.61% |
| 2024-12-31 | -43.46% |
| 2024-09-30 | -35.67% |
| 2024-06-30 | -35.86% |
| 2024-03-31 | -35.45% |
| 2023-12-31 | -36.07% |
| 2023-09-30 | -46.94% |
| 2023-06-30 | -39.89% |
| 2023-03-31 | -38.70% |
| 2022-12-31 | -768.49% |
| 2022-09-30 | -636.82% |
| 2022-06-30 | -198.82% |
| 2022-03-31 | -197.57% |
| 2021-12-31 | -118.78% |
| 2021-09-30 | -108.04% |
| 2021-06-30 | -81.74% |
| 2021-03-31 | -60.23% |
| 2020-12-31 | -394.82% |
